Aid reductionIn effectSocial security and healthcareNational
Alzheimer's disease drugs no longer reimbursed
An order of 29 May 2018 removes from the list of medicines reimbursable to insured persons, from 1 August 2018, products containing donepezil, galantamine, rivastigmine and memantine (Aricept, Reminyl, Exelon, Ebixa and generics), following opinions of the Transparency Committee of the French National Authority for Health (HAS) finding an insufficient medical benefit.
Measure originators
InitiatorGVT
AgnĂšs Buzyn
Gouvernement
InitiatorGVT
GĂ©rald Darmanin
Gouvernement
Impact on public finances
No official estimate found for this measure.
Effective date
1 August 2018
Measure impact
Alzheimer's patients treated with these drugs: no longer covered by health insurance from 1 August 2018. The order covers 242 presentations.
Official references
Law number: ArrĂȘtĂ© du 29 mai 2018 (radiation de la liste des spĂ©cialitĂ©s remboursables)
Official Journal: JORF n° 0124 du 1er juin 2018, texte n° 20
Procedure timeline
Follow the progress of this fiscal measure through the different stages of the parliamentary procedure.
100%
2 / 2 steps
Completed
1 August 2018Entry into force
Application
Immédiate ou à la date prévue
Radiation effective : fin du remboursement des quatre médicaments
Completed
1 June 2018Publication in Official Journal
Publication
Actors
AgnĂšs Buzyn, GĂ©rald Darmanin
Publication au JORF n° 0124 de l'arrĂȘtĂ© du 29 mai 2018 signĂ© par la ministre des SolidaritĂ©s et de la SantĂ© et le ministre de l'Action et des Comptes publics